Information  X 
Enter a valid email address

Company Name matching 'Herantis Pharma Oyj'

Date
Time Source
Company
Announcement
02 Dec 2019 6:00 pm GNW   Herantis Pharma Oyj Herantis Pharma Plc's directed share issue is oversubscribed multiple times and completed as planned
11 Nov 2019 7:00 am GNW   Herantis Pharma Oyj Herantis Pharma Plc commences a directed share issue, contemplates secondary listing on Nasdaq First North Growth Market Sweden and expands its management team
04 Nov 2019 7:00 am GNW   Herantis Pharma Oyj Herantis Pharma publishes newsletter for September-October
02 Sep 2019 7:00 am GNW   Herantis Pharma Oyj Herantis Pharma publishes newsletter for July-August
28 Aug 2019 7:00 am GNW   Herantis Pharma Oyj Herantis Pharma Plc announces half year financial report January 1 - June 30, 2019 (unaudited)
01 Jul 2019 7:00 am GNW   Herantis Pharma Oyj Herantis Pharma publishes newsletter for May-June
31 May 2019 6:00 am GNW   Herantis Pharma Oyj Herantis Pharma Plc’s nomination of Vice Chairman
06 May 2019 7:00 am GNW   Herantis Pharma Oyj Herantis Pharma publishes newsletter for March-April
23 Apr 2019 7:00 am GNW   Herantis Pharma Oyj Herantis Pharma Announces 12-Month Follow-Up Review from Phase 1 Lymfactin Trial in Breast Cancer-Associated Lymphedema
28 Mar 2019 7:00 am GNW   Herantis Pharma Oyj Herantis Pharma Announces Expansion of its Phase 2 Study AdeLE in Breast Cancer Associated Lymphedema with Two Centers in Sweden
12 Mar 2019 3:00 pm GNW   Herantis Pharma Oyj Herantis Pharma Plc Announces Positive Outcome of Directed Share Issue Raising EUR 5.8 Million
28 Feb 2019 7:00 am GNW   Herantis Pharma Oyj Herantis Pharma Plc's Financial Statements Release January 1 - December 31, 2018
15 Feb 2019 7:31 am GNW   Herantis Pharma Oyj Notice to convene Herantis Pharma Plc's Extraordinary General Meeting of shareholders
  7:00 am GNW   Herantis Pharma Oyj Herantis Pharma Plc is planning a directed share issue and prepares for a contemplated secondary listing on the First North Stockholm marketplace
06 Jul 2018 7:00 am GNW   Herantis Pharma Oyj Herantis Pharma initiates non-invasive CDNF development program, announces licensing agreement with University of Helsinki
13 Jun 2018 7:00 am GNW   Herantis Pharma Oyj Herantis Pharma announces initiation of Phase 2 study for Lymfactin® gene therapy in secondary lymphedema
16 Apr 2018 7:00 am GNW   Herantis Pharma Oyj Herantis Pharma announces positive interim data from Lymfactin study in secondary lymphedema
14 Feb 2018 7:00 am GNW   Herantis Pharma Oyj Herantis Pharma opening recruitment in Parkinson's disease study in Helsinki and Lund based on favorable first CDNF safety assessment
08 Feb 2018 7:00 am GNW   Herantis Pharma Oyj Herantis Pharma completes patient enrolment in Phase 1 study of Lymfactin gene therapy for secondary lymphedema and has submitted Phase 2 application
09 Nov 2017 5:00 pm GNW   Herantis Pharma Oyj Herantis Pharma Plc's directed share issue
27 Sep 2017 7:00 am GNW   Herantis Pharma Oyj Herantis Pharma has initiated patient recruitment and consented first patient in CDNF study in Parkinson's disease
15 Sep 2017 6:30 am GNW   Herantis Pharma Oyj Herantis Pharma receives Life Sciences Nordic Stars Award
22 Jun 2017 7:00 am GNW   Herantis Pharma Oyj Herantis Pharma's Lymfactin study advances to last patient cohort, company announces initial plans for continued development
23 Mar 2017 10:30 am GNW   Herantis Pharma Oyj Herantis Pharmas clinical study with CDNF in Parkinsons disease authorized in Sweden
06 Mar 2017 8:00 am GNW   Herantis Pharma Oyj Herantis Pharma's clinical study with Lymfactin advances to high dose level
12 Dec 2016 7:00 am GNW   Herantis Pharma Oyj Herantis Pharma's Parkinson study wins EUR 6.0 million grant from the European Union Horizon 2020 program
25 Oct 2016 7:02 am GNW   Herantis Pharma Oyj Herantis Pharma plc and Renishaw plc sign collaboration agreement on Parkinson's study
30 Jun 2015 8:00 am GNW   Herantis Pharma Oyj Herantis Pharma granted almost 3 million Euro government loan for Parkinson study
11 Mar 2015 8:00 am GNW   Herantis Pharma Oyj Herantis Pharma's Phase 2 Dry Eye study recruitment completed ahead of schedule
27 Feb 2015 8:01 am GNW   Herantis Pharma Oyj Herantis Pharma financial statements report 2014
07 Jan 2015 7:00 am GNW   Herantis Pharma Oyj Herantis Pharma has initiated Phase 2 study with Cis-UCA Eye Drops in Patients with Dry Eye Syndrome, results expected in Q3/2015
18 Dec 2014 8:00 am GNW   Herantis Pharma Oyj Herantis Pharma Plc's financial reporting in 2015
08 Sep 2014 6:30 am GNW   Herantis Pharma Oyj Herantis Pharma announces FDA clearance of IND ...
11 Jun 2014 7:00 am GNW   Herantis Pharma Oyj Trading in the shares of Herantis Pharma to com...
02 Jun 2014 7:00 am GNW   Herantis Pharma Oyj Herantis Pharma successfully completes its init...


Company Announcements Archive »

 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t